Biogen (Uk) Ltd company information, Employees & Contact Information

Layoff Tracker: Alector Nearly Halves Workforce Following Dementia Drug Phase III Failure BioSpace

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease by the European Commission Biogen

In UK, it's strike 2 for Alzheimer's treatments from Lilly and Biogen/Eisai Fierce Pharma

U.K. decision blocks a pair of Alzheimer’s drugs from access through its national health service statnews.com

NHS England's Transition From Biogen's Drug To Sandoz's Biosimilar Sparks Alarm As Multiple Sclerosis Patients Report Severe Effects Yahoo Finance

Kylie Bromley - Biogen - Board Member Association of the British Pharmaceutical Industry (ABPI)

Biogen Energy, Oil & Gas magazine

Biogen opens seventh UK food waste recycling plant Waste Today -

Biogen acquires portfolio of five UK AD plants Bioenergy Insight

UK biogas company Biogen acquires five AD plants from Ingenious EUWID Recycling and Waste Management

Leqembi® (lecanemab) Authorized for Early Alzheimer’s Disease in Great Britain Biogen

Biogen, Eisai’s Leqembi Gets UK Approval but Deemed Too Expensive by NICE BioSpace

The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer’s Disease Biogen

“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in China Biogen

Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in Australia Biogen

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union Biogen

Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union Biogen

Benefits Biogen

Biogen Announces Agreement to Acquire Nightstar Therapeutics to Establish Clinical Pipeline of Gene Therapy Candidates in Ophthalmology Biogen

Biogen begins operations at food waste AD plant in the U.K. Biomass Magazine

Eisai, Biogen's Leqembi nabs UK nod, but reimbursement remains elusive Fierce Pharma

Biogen Acquires UK Biotech Developing Gene Therapy for Blindness Labiotech.eu

Biogen plots 2028 headquarters shift to new 'innovation hub' in Cambridge Fierce Pharma

In the UK, Eisai and Biogen seek to extend Alzheimer’s treatment flexibility The Pharma Letter

Cost-effectiveness agency clears Biogen’s Spinraza for UK patients BioPharma Dive

Biogen Inc. (BIIB) Partners with Stoke Therapeutics to Tackle Dravet Syndrome Yahoo! Finance UK

Biogen secures extended access agreement for Spinraza Pharmaceutical Technology

Biogen continues growth with acquisition of AD operator Tamar Energy resource.co

Biogen acquired by infrastructure investment firm letsrecycle.com

More R&D Fat is Trimmed as Biogen Closes Doors on UK’s Convergence Pharma BioSpace

UK launch for Biogen’s biosimilar infliximab PharmaTimes

Shock as NICE turns down Biogen’s SMA therapy PMLiVE

Biogen acquires five AD plants Materials Recycling World

Biogen launches Remicade biosimilar in the UK PMLiVE

Biogen to bolster rare disease treatments with £5.4 billion Reata acquisition North Wales Chronicle

Biogen acquires gene therapy company Nightstar Therapeutics Association of Optometrists (AOP)

Global biotechnology firm opens new UK and Ireland headquarters in Maidenhead Maidenhead Advertiser

It’s another big tick for Bygrave green energy plant as Biogen cheers industry recognition Royston Crow

Biogen respond after councillors call on Environment Agency to close plant Basingstoke Gazette

Green light for Northamptonshire AD plant letsrecycle.com

Biogen acquires Greenfinch engineering company Farmers Weekly

Digestion plant not to blame for unpleasant odour Halstead Gazette

Waste plants' bid to relax regulations Halstead Gazette

Biogen acquires Tamar Energy Materials Recycling World